{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:birinkibart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:ozuriftamab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:sonesitatug [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:eurestobart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:idestopoetin alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:pamlectabart tismanitin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT04375878: Phase 2 Interventional Completed Exocrine Pancreatic Insufficiency (EPI)
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN